Verastem Oncology Begins FDA Submission for Accelerated Approval of New Cancer Treatment, Seeks Priority Review for Innovative Ovarian Cancer Drug Combo
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has initiated the rolling submission of a New Drug Application (NDA) to